As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment.
NEXGEL (NXGL) issued a letter to its shareholders from Chief Executive Officer, Adam Levy, and is providing guidance for 2024 and 2025. “2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback